Seeking Alpha

Henry McCusker's  Instablog

Henry McCusker
Send Message
Editor and Publisher ... Henry enters his twelve (12) year at Scimitar's RegMed Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and high-impact synthesis. He was VP -... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • ThermoGenesis (KOOL) Q2/13 And 1st 6 Months Results 0 comments
    Feb 13, 2013 9:09 AM

    A net loss of $563 K, or $0.03 per share

    A net loss of $563 K, or $0.03 per share in Q2/13, compared with a net loss of $1.3 M, or $0.08 per share, in Q2/12.

    For Q2 ended 12/ 31/12, net revenues were $4.8 M compared to revenues to revenues of $4.1 M in Q1/13 and $4.77 in Q2/11. Revenues for Q2/13 versus Q2/12 reflect increased sales of BioArchive(NYSE:R) System devices, offset by declines in BioArchive disposable revenues, as well as CryoSeal product sales--which the KOOL divested in Q1/13. Costs of revenues were $2.826 M with a gross profit of $1.97 M. SG&A expenses were $1.82M while R&D expenses were $714 K with total operating expense logging in at $2.53 M.

    • KOOL ended the quarter with $7.5 M in cash compared with $8.8 M at Q1/13 and $7.9 M in FY12. The KOOL's backlog at the end of Q2 was approximately $714 K.

    The first six months of FY13: KOOL <a 6/29 year end> reported net income of $432 K, or $0.03 per diluted share, compared to a net loss of $2.5 M, or $0.15 per share, in the 1st 6 months of 2012. The results for the 1st 6 months of 2013 include a gain on sale of $2 M related to the CryoSeal transaction. KOOL also has encouraging data from the critical limb ischemia (NYSE:CLI) clinical evaluation of the MXP in Naples; a P1 study that used the MXP platform to produce cell concentrate for use in treating peripheral artery disease patients with CLI.

    The Bottom line: Q2 demonstrated improvement in gross margins and reduce operating expenses and the net loss by more than 50% versus Q2/12. Revenues increased nearly $700 K versus Q1/13. Together with the $500 K, KOOL received at the end of Q2 divestitures have generated ... a total of $3.5 M in cash with $2.5 M received in the last 6 months. Restructuring and streamlining initiatives have reduced operating and overhead expenses by more than $2 M annually.

    Their cash position is good … compared to the past ... so expect KOOL to pick up the price appreciation to above the NASDAQ limit of $1.00. On 11/15/12, KOOL received a notice from the NASDAQ notifying them that for 30 consecutive business days and have been provided with 180 calendar days (until 5/14/13) to regain compliance. The key will be breaking beyond the 50 day moving average of $0.93 and the comparable 200 day of $0.93. Momentum has been slow due to moderate volume which has been well below the 10 day numbers. KOOL had 1 day of compliance since 1/2/13. Ranking - BUY and a target pricing of $1.10 to $1.20 in the next 6 months.

    KOOL closed at $0.98, down $0.01 or -0.61%.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

    Themes: earnings
Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.